The ‘Global HUMIRA (Adalimumab Drug) Market Growth, Size, Share, Price, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global HUMIRA (Adalimumab Drug) market, assessing the market on the basis of its segments like indication, type, dosage strength, drug type, route of administration, distribution channel, and major regions.
The report studies the latest updates in the market, along with their impact across the market. It also analyses the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.
The key highlights of the report include:
Market Overview (2016-2031)
- Forecast CAGR (2023-2031): 1%
The HUMIRA (Adalimumab drug) market is driven by several factors, including an increasing prevalence of autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as a growing ageing population. HUMIRA is a biologic drug that is used to treat a variety of autoimmune conditions, and its effectiveness in treating these conditions has led to its widespread use and popularity among patients and healthcare providers. Additionally, the increasing adoption of biologic drugs in the treatment of autoimmune diseases is also driving the market growth.
Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/humira-adalimumab-drug-market/requestsample
Another key driver of the HUMIRA market is the increasing availability of biosimilars, which are cheaper alternatives to the original drug. This has led to a decrease in the cost of treatment for patients, making it more accessible to a larger population. The increasing use of advanced technologies for the development and production of biologic drugs is also driving market growth.
Moreover, the increasing R&D activities and the launch of new drugs in the market are also expected to drive the HUMIRA market in the coming years. The rising awareness among people regarding the availability of effective treatments for autoimmune diseases is also expected to drive the market growth.
However, the market growth may be hindered by the high cost of treatment and the availability of alternative treatments. Additionally, the risk of side effects associated with the use of HUMIRA may also affect market growth. Nevertheless, the increasing demand for more effective treatments for autoimmune diseases is expected to drive the market growth in the forecast period.
HUMIRA (Adalimumab Drug) Market Segmentation
HUMIRA (adalimumab) is a biologic medication that is used to treat a variety of inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. It works by blocking a specific protein, called tumour necrosis factor (TNF), which is involved in the inflammatory process. HUMIRA is administered by injection under the skin, usually once or twice a month, depending on the condition being treated. It is a prescription medication and should only be used under the guidance of a healthcare provider.
Read Full Report with Table of Contents: https://www.expertmarketresearch.com/reports/humira-adalimumab-drug-market
Market Breakup by Indication
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Chronic Plaque Psoriasis
- Crohn’s Disease
- Ulcerative Colitis
- Psoriatic Arthritis
Market Breakup by Type
Market Breakup by Dosage Strength
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channels
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
HUMIRA (Adalimumab Drug) Market Trends
In recent years, the market for HUMIRA has seen significant growth due to an increase in the number of patients being diagnosed with these conditions, as well as the drug’s effectiveness in treating them.
In 2020, AbbVie, the manufacturer of HUMIRA, announced that it had reached a settlement agreement with several generic drug manufacturers, allowing them to begin selling biosimilars of the drug in the United States starting in 2023. This is expected to lead to significant price reductions for HUMIRA, making it more affordable for patients.
In addition, AbbVie has also been working to expand the indications for HUMIRA, such as gaining FDA approval for its use in treating paediatric patients with uveitis, a form of eye inflammation. This further expands the potential patient population for the drug.
Furthermore, the company has also been developing new formulations of HUMIRA, such as a self-injectable pen and a subcutaneous injection, to make administration of the drug more convenient for patients.
Overall, the HUMIRA market is expected to continue to grow in the coming years, driven by increasing patient population, the drug’s effectiveness, and new formulations and indications. However, the market is also expected to face increased competition from biosimilars, which is likely to lead to price reductions for the drug.
Competitive Landscape of HUMIRA (Adalimumab Drug) Market
The major players in the market report are AbbVie Inc., Amgen Inc., Fresenius Kabi AG, Celltrion Healthcare Co Ltd, Alvotech Ehf., Bio-Thera Solutions Ltd., Zydus Lifesciences Limited, Hetero Healthcare Ltd., Innovent Biologics, Inc., Novartis International AG (Sandoz), Reliance Life Sciences Pvt. Ltd., Terumo Corp., Torrent Pharmaceuticals Ltd., and Samsung C&T Corporation. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Read More Reports:
Healthcare Big Data Analytics Market: https://newssummits.com/healthcare-big-data-analytics-market-size-share-industry-report-growth-analysis-overview-key-players-and-forecast-2023-2031/
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Ian Bell, Business Consultant
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA